A latest report has been added to the wide database of Biologics Safety Testing Market by Infinium Global Research. This report
studies the Biologics Safety Testing Market by instruments & services (instruments, kits & reagents and services), test type (bioburden
tests, endotoxin tests, adventitious agent detection tests, cell line authentication and characterization tests, residual host contaminant
detection tests, adventitious agent detection tests and other test), market status and outlook of global and major regions, from
manufacturers, and end industries. The objective of the study is to identify market sizes of different segments & countries in recent
years and to forecast the values for the next six years. Biologics Safety Testing Market provides opportunities in micro markets for
stakeholders to invest along with the detailed analysis of competitive landscape, latest trends, and product offerings of the major
companies in the Biologics Safety Testing Market. According to report the global biologics safety testing market is expected to grow at
a CAGR between 12.0% and 12.5 % over the forecast period of 2017 - 2023.
Kits & Reagents are estimated to account for the largest share of the market in 2017
By instrument and service, the biologics safety testing market is classified into Instruments, Kits & Reagents and Services. The kits &
reagents segment is expected to lead the global biologics safety testing in 2017. Factors driving the growth of this segment include
increasing and continuous use of kits & reagents, rising prevalence of genetic disorder as well as growing advancements in the creation
of kits & reagents.
Vaccine & Therapeutics are estimated to command the largest share of the market during the forecast period
On the basis of application, the biologics safety testing market is categorized into Vaccine & Therapeutics Development, Tissue and
Tissue-Related Products Testing, Blood and Blood-Related Products Testing, Stem Cell Research and Cellular and Gene Therapy. The
vaccine & therapeutics segment is estimated to account for the largest share of the global biologics safety testing market during the
forecast period. Increasing target diseases, growing investment in development of new vaccines and reduced toxicity are the key
factors driving the growth of this application segment.
North America is estimated to command the largest share of the market
Based on region, the biologics safety testing market is segmented into North America, Europe, Asia, and the Rest of the World (RoW).
North America is expected to dominate the biologics safety testing market in 2017. This is attributed to factors such as rising
prevalence of chronic diseases in the region, presence of key market players as well as growing investment in R&D activities by the key